CAPR Financials

Income Statement
MetricQ1 2026Q4 2025Q3 2025Q2 2025Q1 2025
Revenue
0
0
0
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
0
0
0
Operating Expenses
36.8M
+26.1%
29.2M
+10.9%
26.3M
-5.2%
27.7M
+11.0%
25.0M
R&D
27.4M
+18.3%
23.1M
+13.6%
20.4M
-7.7%
22.0M
+16.6%
18.9M
SG&A
9.4M
+56.0%
6.0M
+1.7%
5.9M
+4.5%
5.7M
-6.5%
6.1M
Operating Income
-36772853
-26.1%
-29156008
-10.9%
-26284040
+5.2%
-27719134
-11.0%
-24982948
EBITDA
-36238183
-26.5%
-28653421
-11.1%
-25789314
+5.3%
-27232856
-10.8%
-24577498
Net Income
-33941345
-12.5%
-30170914
-22.8%
-24570647
+5.2%
-25910791
-6.2%
-24391594
EPS (Basic)
$-0.59
+4.8%
$-0.62
-14.8%
$-0.54
+5.3%
$-0.57
-7.5%
$-0.53
EPS (Diluted)
$-0.59
+4.8%
$-0.62
-14.8%
$-0.54
+5.3%
$-0.57
-7.5%
$-0.53
Shares (Diluted)
57.4M
+17.6%
48.9M
+6.9%
45.7M
+0.0%
45.7M
+0.2%
45.6M
Capricor Therapeutics (CAPR) โ€” Financials